Search

Displaying results 2011 - 2020 of 10000 in total
  1. Drug

    Idebenone

    go.drugbank.com/drugs/DB09081
    ApprovedInvestigational

    LHON is a mitochondrially inherited degeneration of retinal ganglion cells, resulting in acute central vision loss. … Idebenone is a synthetic analogue of ubiquinone (also known as Coenzyme Q10), a vital cell antioxidant and essential component of the Electron Transport Chain (ETC).

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Regorafenib

    go.drugbank.com/drugs/DB08896
    ApprovedInvestigational

    FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017. … Regorafenib is an orally-administered inhibitor of multiple kinases.

    Categories: UGT1A9 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic Index
  3. Drug

    Ethambutol

    go.drugbank.com/drugs/DB00330
    ApprovedInvestigational

    [L31743] Ethambutol was first described in the literature in 1961.[A229048] It was developed out of a need for therapies active against isoniazid resistant strains of _Mycobacterium tuberculosis_. … Ethambutol is a bacteriostatic agent indicated alongside medications such as [isoniazid], [rifampin], and [pyrazinamide] in the treatment of pulmonary tuberculosis.

    Synonyms: (+)-N,N'-bis(1-(hydroxymethyl)propyl)ethylenediamineProducts: E-BUTOL TABLET 400 mg
  4. Drug

    Haemagglutinin-strain A(H3N2)

    go.drugbank.com/drugs/DB15475
    ApprovedInvestigational

    Mixtures: Afluria Tetra Injektionssuspension in einer FertigspritzeSynonyms: Haemagglutinin-strain A (H3N2), Haemagglutinin-strain A(H3N2)
  5. Drug

    Haemagglutinin-strain A(H1N1)

    go.drugbank.com/drugs/DB15476
    ApprovedInvestigational

    Mixtures: Afluria Tetra Injektionssuspension in einer FertigspritzeSynonyms: Haemagglutinin-strain A (H1N1), Haemagglutinin-strain A(H1N1)
  6. Drug

    Vanzacaftor

    go.drugbank.com/drugs/DB18373
    ApprovedInvestigational

    [L52275,A179677] Vanzacaftor was first approved by the US FDA in December 2024 in combination with another CFTR corrector - [tezacaftor], which binds to a different site than vanzacaftor - and [deutivacaftor … ], a CFTR potentiator, for the treatment of patients with responsive CFTR mutations.

  7. Drug

    Apremilast

    go.drugbank.com/drugs/DB05676
    ApprovedInvestigational

    [L7501] In July 2019, apremilast was granted a new FDA approval for the treatment of oral ulcers associated with Behcet's disease, an autoimmune condition that causes recurrent skin, blood vessel, and … [A181244,L7495] Initially approved in 2014, it is marketed by Celgene.

    Synonyms: N-{2-[(1S)-1-(3-Ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide
  8. Drug

    Zolmitriptan

    go.drugbank.com/drugs/DB00315
    ApprovedInvestigational

    Zolmitriptan is a member of the triptan class of 5-hydroxytryptamine(5-HT)<sub>1B/1D/(1F)</sub> receptor agonists used to treat acute migraine. … [A193791] Triptans can be administered alone or in combination with an NSAID like [naproxen], and represent the current "gold standard" for acute migraine treatment.

    Categories: Monoamine Oxidase A SubstratesProducts: ZOLMITRIPTAN AL 5MG, ZOLMITRIPTAN AL 2.5MG
  9. Drug

    Elinzanetant

    go.drugbank.com/drugs/DB18968
    ApprovedInvestigational

    Elinzanetant is a non-hormonal, selective, dual neurokinin 1 (NK-1) and 3 (NK-3) receptor antagonist. … in thermo-regulation.

    Synonyms: 2-(3,5-bis(trifluoromethyl)phenyl)-n-(4-(4-fluoro-2-methylphenyl)-6-((7s,9as)-7-(hydroxymethyl)hexahydropyrazino(2,1-c)(1,4)oxazin-8(1h)-yl)-3-pyridinyl)-n,2-dimethylpropanamide, Benzamide, 3-(5-methyl-2-tbenzeneacetamide, n-(4-(4-fluoro-2-methylphenyl)-6-((7s,9as)-hexahydro-7-(hydroxymethyl)pyrazino(2,1-c)(1,4)oxazin-8(1h)-yl)-3-pyridinyl)-n,.alpha.,.alpha.
  10. Drug

    Danicopan

    go.drugbank.com/drugs/DB15401
    ApprovedInvestigational

    [L50381] It was first approved in January 2024 in Japan for patients with PNH,[A263506,L50416] shortly after which the EMA adopted a positive opinion and recommended granting it marketing authorization … [A263501,L50411] Danicopan is a small molecule complement factor D inhibitor that selectively blocks the alternative pathway, thereby working to address extravascular hemolysis when used in conjunction

    Synonyms: (2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide, (2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidine-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridine-2-yl)-4-fluoropyrrolidine-2-carboxamide